


R² is -CF₃.



each R is independently hydrogen or C₁₋₆ aliphatic.

~~R¹ is C₃₋₁₀-aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each of which is optionally substituted;~~

~~R² is R, halogen, haloalkyl, OR, SR, CN, NO₂, SO₂R, SOR, C(O)R, CO₂R, C(O)N(R)₂, NRC(O)R, NRC(O)N(R)₂, NRSO₂R, or N(R)₂;~~


~~each R is independently hydrogen, C₁₋₆-aliphatic, C₃₋₁₀-aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each of which is optionally substituted; or~~

two R groups on the same atom are taken together with the atom to which they are attached to form a C₃₋₁₀-aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each of which is optionally substituted.

2. The compound of claim 1, wherein A' is C=O, CH₂, CHOH, or NH.


3. The compound of any preceeding claim, wherein L is a divalent group selected from phenyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl, furanyl, furazanyl, imidazolidinyl, imidazolyl, imidazolyl, 1H-indazolyl, indolenyl, isoxazolyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolidinyl, pyrimidinyl, piperazinyl, piperidinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolyl, pyrazolyl, pyridazinyl, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, tetrahydrofuranyl, thiazolyl, thienyl, thiophenyl, oxetanyl, and azetidiny, each of which is optionally substituted.

4. The compound of any preceeding claim, wherein L is a divalent group selected from



5. The compound of any preceeding claim, wherein R¹ is C₃₋₁₀-aryl.


63. The compound of Claim 1 any preceeding claim, wherein R¹ is




7. ~~The compound of any preceeding claim, wherein R^2 is C_{1-6} aliphatic or 3-7 membered heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.~~

8. ~~The compound of any preceeding claim, wherein R^2 is methyl, ethyl, propyl, i-propyl, n-butyl, i-butyl, t-butyl, straight chain or branched pentyl, or straight chain or branched hexyl, or R^2 is a 4 membered heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.~~

9. ~~The compound of any preceeding claim, wherein R^2 is CF_3 ,~~




104. The compound of claim 1, of formula **I-a**,



I-a;


or a pharmaceutically acceptable salt thereof.

115. The compound of claim 1, of formula **I-c**,

**I-c;**


or a pharmaceutically acceptable salt thereof.

~~126.~~ The compound of claim 1, of formula **I-e**,

**I-e;**







or a pharmaceutically acceptable salt thereof.





~~137.~~ The compound of claim 1, of formula **I-h**,







**I-h;**







or a pharmaceutically acceptable salt thereof.







~~148.~~ The compound of claim 1, selected from ~~Table 1.~~


**1****2****3****4**

5679810

**11****12****13****14****15****16**

**17****18****19****20****21****22**

**23****24****25****26****27****28**



and 29

159. A pharmaceutical composition comprising a compound according to any one of claims 1-8, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable adjuvant, carrier, or vehicle.

~~16. A method for inhibiting IRAK, or a mutant thereof, activity in a patient or in a biological sample, comprising the step of administering to said patient or contacting said biological sample with a compound of claim 1 or a physiologically acceptable salt thereof.~~

10. A pharmaceutical composition comprising the compound of any one of claims 1-8, or a pharmaceutical acceptable salt thereof, for use in treating an IRAK-mediated disorder in a patient in need thereof

~~17. A method for treating an IRAK-mediated disorder in a patient in need thereof, comprising the step of administering to said patient a compound of claim 1.~~

~~18. The method of claim 17, wherein the disorder is selected from Rheumatoid Arthritis, Psoriatic arthritis, Osteoarthritis, Systemic Lupus Erythematosus, Lupus nephritis, Ankylosing Spondylitis, Osteoporosis, Systemic sclerosis, Multiple Sclerosis, Psoriasis, Type I diabetes, Type II diabetes, Inflammatory Bowel Disease (Cronh's Disease and Ulcerative Colitis), Hyperimmunoglobulinemia D and periodic fever syndrome, Cryopyrin-associated periodic syndromes, Schnitzler's syndrome, Systemic juvenile idiopathic arthritis, Adult's onset Still's disease, Gout, Pseudogout, SAPHO syndrome, Castleman's disease, andometriosis; Sepsis, Stroke, Atherosclerosis, Celiac disease, DIRA (Deficiency of IL-1 Receptor Antagonist), Alzheimer's disease, Parkinson's disease, and Cancer.~~

~~1911. A method-pharmaceutical composition comprising compound according to any one of claims 1-8, or a pharmaceutically acceptable salt thereof for use in treating cancer in a subject in need thereof, comprising the step of administering to said subject a compound of claim 1 or a physiologically acceptable salt thereof.~~

~~2012. The method-pharmaceutical composition of claim 18 10, wherein the IRAK-mediated disorder is selected from Rheumatoid Arthritis, Systemic Lupus Erythematosus, Lupus nephritis, and Multiple Sclerosis.~~